Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation

Submitted by Anonymous on

BackgroundSMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) represents a distinct, highly aggressive molecular subtype associated with a poor pro Abstract Background: SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) represents a distinct, highly aggressive molecular subtype associated with a poor prognosis. While immune...

Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials

Submitted by Anonymous on

BackgroundAlthough anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab are extensively used in metastatic colorectal Abstract Background: Although anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab are extensively used in metastatic colorectal cancer therapy, their association...

BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data

Submitted by Anonymous on

AbstractBackground Drug resistance and lack of predicting biomarkers are a major challenge for cancer therapy. The combination of a BRAF inhibitor (BRAFi) together with an anti-EGFR inhibitor (EGFRi) represents a standard of care approach in BRAFV600E metastatic colorectal cancer (mCRC)...

TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

Submitted by Anonymous on

Background Activating mutations in the epidermal growth factor receptor (EGFR), particularly exon 19 deletions and L858R mutation, are frequently observed in non-small cell lung cancer (NSCLC) and confer sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Among these EGFR-TKIs, osimertinib is currently...

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Submitted by Anonymous on

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious adverse events (0%)No dose-limiting toxicities observed.No treatment discontinuations due to adverse events...

Hh and EGFR-Ras signaling promote distinct steps of tumor progression in the Drosophila follicle epithelium

Submitted by Anonymous on

Controlled signaling activity is vital for normal tissue homeostasis and oncogenic signaling activation facilitates tumorigenesis. Here, we combine single-cell transcriptomics with in-depth genetic and imaging analysis to investigate the role of the EGFR-Ras and Hedgehog signaling pathways in homeostasis of...

A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort

Submitted by Anonymous on

Efficacy of EGFR inhibitor-anti-angiogenic combination therapy varies substantially in RAS wild-type advanced colorectal cancer (CRC), and current clinical guidelines lack individualized predictive tools to identify optimal candidates and tailor regimens. This study aimed to develop and externally validate a multi-dimensional...

Loss of LLGL1 Elevates EGFR/RAS/MAPK Signaling and Remodels EMT Markers in Huh-7 Hepatocellular Carcinoma Cells

Submitted by Anonymous on

Open AccessArticle Loss of LLGL1 Elevates EGFR/RAS/MAPK Signaling and Remodels EMT Markers in Huh-7 Hepatocellular Carcinoma Cells by Gökhan YıldızGökhan Yıldız SciProfiles Scilit Preprints.org Google Scholar 1,2,*, Soner KarabulutSoner Karabulut SciProfiles Scilit Preprints.org Google Scholar 2, Tuba DinçerTuba Dinçer SciProfiles...

Subscribe to Newsfeed